Table 3.
Univariate and multivariate analysis of progression-free survival, MCC-specific survival, and overall survival on the basis of MCPyV tumor viral status
| Risk Factor | Hazard Ratio | 95% Confidence Interval | P-Value |
|---|---|---|---|
| Progression-Free Survival | |||
| Univariate analysis | |||
| Tumor viral status | |||
| MCPyV-positive | Reference | Reference | — |
| MCPyV-negative | 1.80 | 1.22–2.64 | 0.003 |
| Multivariate analysis excluding stage | |||
| Tumor viral status | |||
| MCPyV-positive | Reference | Reference | — |
| MCPyV-negative | 1.77 | 1.20–2.62 | 0.004 |
| Age | 1.01 | 0.99–1.02 | 0.27 |
| Sex | |||
| Female | Reference | Reference | — |
| Male | 1.73 | 1.14–2.62 | 0.010 |
| Immunosuppression | |||
| Absent | Reference | Reference | — |
| Present | 2.14 | 1.15–4.01 | 0.017 |
| Multivariate analysis including stage | |||
| Tumor viral status | |||
| MCPyV-positive | Reference | Reference | — |
| MCPyV-negative | 1.55 | 0.96–2.49 | 0.073 |
| Age | 1.02 | 1.00–1.03 | 0.063 |
| Sex | |||
| Female | Reference | Reference | — |
| Male | 1.76 | 1.07–2.91 | 0.027 |
| Immunosuppression | |||
| Absent | Reference | Reference | — |
| Present | 2.28 | 1.12–4.63 | 0.022 |
| Stage | |||
| I | Reference | Reference | — |
| II | 1.61 | 0.91–2.86 | 0.10 |
| III | 1.42 | 0.87–2.32 | 0.16 |
| IV | Omitted | Omitted | — |
| MCC-Specific Survival | |||
| Univariate analysis | |||
| Tumor viral status | |||
| MCPyV-positive | Reference | Reference | — |
| MCPyV-negative | 1.79 | 1.14–2.80 | 0.011 |
| Multivariate analysis excluding stage | |||
| Tumor viral status | |||
| MCPyV-positive | Reference | Reference | — |
| MCPyV-negative | 1.85 | 1.19–2.89 | 0.006 |
| Age | 1.00 | 0.99–1.02 | 0.57 |
| Sex | |||
| Female | Reference | Reference | — |
| Male | 1.84 | 1.13–2.99 | 0.014 |
| Immunosuppression | |||
| Absent | Reference | Reference | — |
| Present | 2.64 | 1.29–5.41 | 0.008 |
| Multivariate analysis including stage | |||
| Tumor viral status | |||
| MCPyV-positive | Reference | Reference | — |
| MCPyV-negative | 1.50 | 0.88–2.58 | 0.14 |
| Age | 1.00 | 0.98–1.02 | 0.90 |
| Sex | |||
| Female | Reference | Reference | — |
| Male | 1.93 | 1.11–3.33 | 0.019 |
| Immunosuppression | |||
| Absent | Reference | Reference | — |
| Present | 3.94 | 2.14–7.26 | <0.001 |
| Stage | |||
| I | Reference | Reference | — |
| II | 1.79 | 0.77–4.17 | 0.18 |
| III | 2.92 | 1.52–5.63 | 0.001 |
| IV | 5.29 | 2.21–12.65 | <0.001 |
| Overall Survival | |||
| Univariate analysis | |||
| Tumor viral status | |||
| MCPyV-positive | Reference | Reference | — |
| MCPyV-negative | 1.32 | 0.93–1.87 | 0.12 |
| Multivariate analysis excluding stage | |||
| Tumor viral status | |||
| MCPyV-positive | Reference | Reference | — |
| MCPyV-negative | 1.25 | 0.90–1.73 | 0.180 |
| Age | 1.05 | 1.03–1.06 | <0.001 |
| Sex | |||
| Female | Reference | Reference | — |
| Male | 1.52 | 1.11–2.06 | 0.008 |
| Immunosuppression | |||
| Absent | Reference | Reference | — |
| Present | 2.39 | 1.29–4.44 | 0.006 |
| Multivariate analysis including stage | |||
| Tumor Viral Status | |||
| MCPyV Positive | Reference | Reference | — |
| MCPyV Negative | 1.30 | 0.86–1.96 | 0.21 |
| Age | 1.04 | 1.02–1.06 | <0.001 |
| Sex | |||
| Female | Reference | Reference | — |
| Male | 1.47 | 1.01–2.14 | 0.044 |
| Immunosuppression | |||
| Absent | Reference | Reference | — |
| Present | 3.25 | 1.81–5.81 | <0.001 |
| Stage | |||
| I | Reference | Reference | — |
| II | 1.60 | 0.91–2.81 | 0.10 |
| III | 2.03 | 1.30–3.17 | 0.002 |
| IV | 3.38 | 1.91–5.97 | <0.001 |
Abbreviations: MCC, Merkel cell carcinoma; MCPyV, Merkel cell polyomavirus.